Importantly, the JAK1/STAT3 pathway was previously shown to alter proteasome inhibitor sensitivity in multiple myeloma [68], and therefore could possibly induce bortezomib resistance in the case of TKI-resistant CML. The gene discussed is JAK1; the disease is plasma cell myeloma.